VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
the Cancer Therapy Advisor take:
Bortezomib, cyclophosphamide, and dexamethasone (VCD) is preferable to bortezomib, doxorubicin, and dexamethasone (PAd) as induction therapy for transplant-eligible patients with newly diagnosed multiple myeloma, a study published in the journal Leukemia has shown.
For the phase III trial, researchers enrolled 504 patients with newly diagnosed multiple myeloma who were eligible for stem cell transplantation. Patients either received VCD or PAd.
Results showed that 37.0% of patients in the VCD group achieved a very good partial response or better compared with 34.3% of patients in the PAd group (P = 0.001). In addition, 0.4% and 4.8% of those that received VCD and PAd, respectively, had progressive disease.
In regard to safety, serious overall adverse events and those related to thromboembolic events occurred more frequently in the PAd cohort (32.7% vs 24.0%; P = 0.04 and 2.8% vs 0.4%; P = 0.04). Neuropathy also occurred more frequently in the PAd group, while leukocytopenia and neutropenia occurred more commonly in the VCD arm.
The findings suggest that VCD is as effective as PAd and has a more favorable toxicity profile.
Bortezomib, cyclophosphamide, and dexamethasone is preferable as induction therapy for newly diagnosed multiple myeloma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma